On the HCPLive Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.
February 7th 2025
Emblaveo combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management
April 3, 2025
Register Now!
A Tethered Approach to Type 2 Diabetes Care – Connecting Insulin Regimens with Digital Technology
View More
Surv.AI Says™: What Clinicians and Patients Are Saying About Glucose Management in the Technology Age
View More
Clinical ShowCase™: Forming a Personalized Treatment Plan for a Patient With ANCA-Associated Vasculitis
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)
View More
Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies
View More
Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis
View More
Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis
View More
Multidisciplinary Approach to Opioid Reduction Can Achieve Dosage Goals
In light of issues concerning opioid misuse running parallel to the tenfold increase of prescription opioid use over the past 20 years, a team of researchers have developed an ongoing study examining results of a pilot program aimed at reducing patients' use of pain medications.
FDA Limits Usage, Duration of Hyponatremia Drug Due to Observed Liver Damage Risk
Citing an increased risk of liver injury observed in recent clinical trials, the US Food and Drug Administration (FDA) has limited Samsca (tolvaptan) treatment to 30 days and recommended the oral selective vasopressin V2-receptor antagonist be discontinued in patients with signs of liver disease or symptoms of liver injury.
FDA Approves Kcentra to Reverse Warfarin-Induced Anticoagulation
The US Food and Drug Administration (FDA) today approved Kcentra [prothrombin complex concentrate (human)] for the urgent reversal of anticoagulation induced by vitamin K antagonist (VKA) therapies such as warfarin in adult patients with acute major bleeding.
New Diabetes Management Guidelines Consider Concurrent Conditions
In diagnosing a patient with type 2 diabetes, an endocrinologist or primary care physician may struggle with developing healthy treatment targets when comorbid conditions like obesity and hypoglycemia are at play.
Adding Probiotic Compound to H. Pylori Eradication Treatment Doesn't Curb Adverse Effects
After noticing the ample adverse effects of second-line Helicobacter pylori eradication treatments that utilize tetracycline, furazolidone and proton-pump inhibitors, one group of gastroenterologists set to work adding a probiotic compound to the regimen in an attempt to increase the stomach bacteria's eradication rate while curbing those unwanted effects.
Pain Medicine Slowly Making Progress in Value-Based Care System
The advent of accountable care organizations, bundled payments, and other reforms under the Affordable Care Act has steered the focus of health care delivery from quantity to quality, but where exactly do pain medicine providers fit into the new value-based care model, and how can it benefit their patients?
Aubagio Decelerates Multiple Sclerosis Flare-Ups
Approved by the FDA in September 2012, Genzyme's Aubagio (teriflunomide tablets) is a once-daily oral treatment shown to reduce relapses, slow physical disability progression and reduce the number of brain lesions detected by magnetic resonance imaging (MRI) in patients with relapsing forms of multiple sclerosis (MS).
VIDEO: Many Heart Failure Patients Cannot Tolerate Recommended Doses of Beta Blockers
March 11th 2013Jeffrey S. Borer, MD, of the Howard Gilman Institute for Heart Valve Disease, discusses treating patients with heart failure with beta-blockers and whether there are any patients in this group who are not good candidates for this treatment.
Modern Technology Reveals Atherosclerosis Was Prevalent in Ancient Populations
March 11th 2013Investigators in the expanded HORUS trial using CT scans of ancient mummies from multiple populations and geographic regions report finding evidence of probable or definite atherosclerosis in nearly one-third of samples.
Researchers Tie Increased Acute Pancreatitis Risk to Cortisone Tablets
Though the causes of acute pancreatitis are unknown in roughly a quarter of its worldwide patient population, a recent analysis published in JAMA Internal Medicine has discovered a link between increased risk of the disease and medicines containing cortisone.
New Injectable Gel May Prevent Heart Failure After Myocardial Infarction
Bioengineers at the University of California, San Diego have deemed a new injectable hydrogel safe and effective for repairing tissue damage caused by myocardial infarction, providing a platform to bring the gel to clinical trials within the next year.
Prescription Opioids: Putting the Genie Back in the Bottle
February 15th 2013The push to provide better pain care and ensure adequate analgesia for patients living with chronic pain led to liberalized opioid prescription practices that have been accompanied by a massive increase in the abuse, misuse, and diversion of prescription opioids. Efforts to combat this include technological remedies such as "abuse-deterrent" formulations of opioids and educational approaches such as the REMS program approved by the FDA in 2012.